1887

Chapter 12 : Antiherpesvirus Agents

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Antiherpesvirus Agents, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819439/9781555819422.ch12-1.gif /docserver/preview/fulltext/10.1128/9781555819439/9781555819422.ch12-2.gif

Abstract:

The first effective agents against herpesviruses were nucleoside analogs, such as idoxuridine, vidarabine, and trifluridine. Their use was eventually supplanted by the highly successful drug, acyclovir, which had significantly less toxicity. In early studies, intravenous acyclovir was shown to be superior to vidarabine for treating herpes simplex virus (HSV) encephalitis in healthy hosts and varicella zoster virus (VZV) infections in immunosuppressed subjects and to be equivalent to vidarabine in treating neonatal HSV infections.

Citation: Gordon C, Kubin C, Hammer S. 2017. Antiherpesvirus Agents, p 215-237. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch12
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Chemical structures of antiherpesvirus agents. (Reprinted with permission from reference [ ]).

Citation: Gordon C, Kubin C, Hammer S. 2017. Antiherpesvirus Agents, p 215-237. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

Chemical structures of investigational antiherpesvirus agents. (Reprinted with permission from reference [ ]).

Citation: Gordon C, Kubin C, Hammer S. 2017. Antiherpesvirus Agents, p 215-237. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555819439.ch12
1. Schaeffer HJ, Beauchamp L, de Miranda P, Elion GB, Bauer DJ, Collins P. 1978. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 272:583585.[PubMed]
2. Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, Vimalachandra D, Craig JC. 2005. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 365:21052115.[PubMed]
3. Burns WH, Sandford GR. 1990. Susceptibility of human herpesvirus 6 to antivirals in vitro. J Infect Dis 162:634637.[PubMed]
4. De Clercq E, Naesens L, De Bolle L, Schols D, Zhang Y, Neyts J. 2001. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol 11:381395.[PubMed]
5. Neyts J, De Clercq E. 1997. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 41:27542756.[PubMed]
6. Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC. 2010. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. J Virol 84:45344542.[PubMed]
7. Coen N, Duraffour S, Snoeck R, Andrei G. 2014. KSHV targeted therapy: an update on inhibitors of viral lytic replication. Viruses 6:47314759[CrossRef].[PubMed]
8. Elion GB. 1982. Mechanism of action and selectivity of acyclovir. Am J Med 73(1A):713.[PubMed]
9. Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM. 1993. Distinguishing acyclovir neurotoxicity from encephalomyelitis. J Intern Med 234:507511.[PubMed]
10. Gnann JW Jr, Barton NH, Whitley RJ. 1983. Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications. Pharmacotherapy 3:275283.[PubMed]
11. Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G. 1993. Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature. Am J Kidney Dis 22:611615.[PubMed]
12. Pasternak B, Hviid A. 2010. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 304:859866.[PubMed]
13. Stone KM, Reiff-Eldridge R, White AD, Cordero JF, Brown Z, Alexander ER, Andrews EB. 2004. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984–1999. Birth Defects Res A Clin Mol Teratol 70:201207.[PubMed]
14. Ashley RL, Corey L. 1984. Effect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virus. J Clin Invest 73:681688.[PubMed]
15. Wagstaff AJ, Faulds D, Goa KL. 1994. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:153205.[PubMed]
16. Furman PA, de Miranda P, St Clair MH, Elion GB. 1981. Metabolism of acyclovir in virus-infected and uninfected cells. Antimicrob Agents Chemother 20:518524.[PubMed]
17. Neyts J, Andrei G, De Clercq E. 1998. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 42:216222.[PubMed]
18. Ljungman P, Ellis MN, Hackman RC, Shepp DH, Meyers JD. 1990. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis 162:244248.[PubMed]
19. Gateley A, Gander RM, Johnson PC, Kit S, Otsuka H, Kohl S. 1990. Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. J Infect Dis 161:711715.[PubMed]
20. Frobert E, Burrel S, Ducastelle-Lepretre S, Billaud G, Ader F, Casalegno JS, Nave V, Boutolleau D, Michallet M, Lina B, Morfin F. 2014. Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France. Antiviral Res 111:3641.[PubMed]
21. Schmidt S, Bohn-Wippert K, Schlattmann P, Zell R, Sauerbrei A. 2015. Sequence analysis of herpes simplex virus 1 thymidine kinase and DNA polymerase genes from over 300 clinical isolates from 1973 to 2014 finds novel mutations that may be relevant for development of antiviral resistance. Antimicrob Agents Chemother 59:49384945.[PubMed]
22. Piret J, Boivin G. 2011. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 55:459472.[PubMed]
23. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. 2003. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 16:114128.[PubMed]
24. Danve-Szatanek C, Aymard M, Thouvenot D, Morfin F, Agius G, Bertin I, Billaudel S, Chanzy B, Coste-Burel M, Finkielsztejn L, Fleury H, Hadou T, Henquell C, Lafeuille H, Lafon ME, Le Faou A, Legrand MC, Maille L, Mengelle C, Morand P, Morinet F, Nicand E, Omar S, Picard B, Pozzetto B, Puel J, Raoult D, Scieux C, Segondy M, Seigneurin JM, Teyssou R, Zandotti C. 2004. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 42:242249.[PubMed]
25. Stránská R, Schuurman R, Nienhuis E, Goedegebuure IW, Polman M, Weel JF, Wertheim-Van Dillen PM, Berkhout RJ, van Loon AM. 2005. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 32:718.[PubMed]
26. Duan R, de Vries RD, Osterhaus AD, Remeijer L, Verjans GM. 2008. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis 198:659663.[PubMed]
27. van Velzen M, van de Vijver DA, van Loenen FB, Osterhaus AD, Remeijer L, Verjans GM. 2013. Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis. J Infect Dis 208:13591365.[PubMed]
28. Schepers K, Hernandez A, Andrei G, Gillemot S, Fiten P, Opdenakker G, Bier JC, David P, Delforge ML, Jacobs F, Snoeck R. 2014. Acyclovir-resistant herpes simplex encephalitis in a patient treated with anti-tumor necrosis factor-α monoclonal antibodies. J Clin Virol 59:6770.[PubMed]
29. Andrei G, Snoeck R. 2013. Herpes simplex virus drug-resistance: new mutations and insights. Curr Opin Infect Dis 26:551560.[PubMed]
30. Piret J, Boivin G. 2014. Antiviral drug resistance in herpesviruses other than cytomegalovirus. Rev Med Virol 24:186218.[PubMed]
31. Malvy D, Treilhaud M, Bouée S, Crochard A, Vallée D, El Hasnaoui A, Aymard M, and the RESSAC Study Group. 2005. A retrospective, case-control study of acyclovir resistance in herpes simplex virus. Clin Infect Dis 41:320326.[PubMed]
32. Schulte EC, Sauerbrei A, Hoffmann D, Zimmer C, Hemmer B, Mühlau M. 2010. Acyclovir resistance in herpes simplex encephalitis. Ann Neurol 67:830833.[PubMed]
33. Coen DM, Kosz-Vnenchak M, Jacobson JG, Leib DA, Bogard CL, Schaffer PA, Tyler KL, Knipe DM. 1989. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci USA 86:47364740.[PubMed]
34. Efstathiou S, Kemp S, Darby G, Minson AC. 1989. The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J Gen Virol 70:869879.[PubMed]
35. Chen SH, Pearson A, Coen DM, Chen SH. 2004. Failure of thymidine kinase-negative herpes simplex virus to reactivate from latency following efficient establishment. J Virol 78:520523.[PubMed]
36. Andrei G, Fiten P, Froeyen M, De Clercq E, Opdenakker G, Snoeck R. 2007. DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions. Antivir Ther 12:719732.[PubMed]
37. Dambrosi S, Martin M, Yim K, Miles B, Canas J, Sergerie Y, Boivin G. 2010. Neurovirulence and latency of drug-resistant clinical herpes simplex viruses in animal models. J Med Virol 82:10001006.[PubMed]
38. Safrin S, Assaykeen T, Follansbee S, Mills J. 1990. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 161:10781084.[PubMed]
39. van Velzen M, van Loenen FB, Meesters RJ, de Graaf M, Remeijer L, Luider TM, Osterhaus AD, Verjans GM. 2012. Latent acyclovir-resistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals. J Infect Dis 205:15391543.[PubMed]
40. Bernstein DI, Ireland J, Bourne N. 2000. Pathogenesis of acyclovir-resistant herpes simplex type 2 isolates in animal models of genital herpes: models for antiviral evaluations. Antiviral Res 47:159169.[PubMed]
41. Besecker MI, Furness CL, Coen DM, Griffiths A. 2007. Expression of extremely low levels of thymidine kinase from an acyclovir-resistant herpes simplex virus mutant supports reactivation from latently infected mouse trigeminal ganglia. J Virol 81:83568360.[PubMed]
42. Boivin G, Edelman CK, Pedneault L, Talarico CL, Biron KK, Balfour HH Jr. 1994. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 170:6875.[PubMed]
43. Morfin F, Thouvenot D, De Turenne-Tessier M, Lina B, Aymard M, Ooka T. 1999. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother 43:24122416.[PubMed]
44. Fillet AM, Dumont B, Caumes E, Visse B, Agut H, Bricaire F, Huraux JM. 1998. Acyclovir-resistant varicella-zoster virus: phenotypic and genetic characterization. J Med Virol 55:250254.[PubMed]
45. van der Beek MT, Vermont CL, Bredius RG, Marijt EW, van der Blij-de Brouwer CS, Kroes AC, Claas EC, Vossen AC. 2013. Persistence and antiviral resistance of varicella zoster virus in hematological patients. Clin Infect Dis 56:335343.[PubMed]
46. Gilbert C, Bestman-Smith J, Boivin G. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 5:88114.[PubMed]
47. Balfour HH Jr, Benson C, Braun J, Cassens B, Erice A, Friedman-Kien A, Klein T, Polsky B, Safrin S. 1994. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 7:254260.[PubMed]
48. Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. 2010. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol 49:151157.[PubMed]
49. Tse E, Kwong YL. 2015. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Exp Mol Med 47:e136.[PubMed]
50. Whitley RJ, Roizman B. 2001. Herpes simplex virus infections. Lancet 357:15131518.[PubMed]
51. Corey L, Nahmias AJ, Guinan ME, Benedetti JK, Critchlow CW, Holmes KK. 1982. A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med 306:13131319.[PubMed]
52. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. 2002. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 34:944948.[PubMed]
53. Kinghorn GR, Turner EB, Barton IG, Potter CW, Burke CA, Fiddian AP. 1983. Efficacy of topical acyclovir cream in first and recurrent episodes of genital herpes. Antiviral Res 3:291301.[PubMed]
54. Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. 2014. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2:CD006866.[PubMed]
55. Numthavaj P, Thakkinstian A, Dejthevaporn C, Attia J. 2011. Corticosteroid and antiviral therapy for Bell's palsy: a network meta-analysis. BMC Neurol 11:1.[PubMed]
56. Wilck MB, Zuckerman RA AST Infectious Diseases Community of Practice. 2013. Herpes simplex virus in solid organ transplantation. Am J Transplant 13(Suppl 4):121127.[PubMed]
57. Ljungman P. 2001. Prophylaxis against herpesvirus infections in transplant recipients. Drugs 61:187196.[PubMed]
58. Rooney JF, Straus SE, Mannix ML, Wohlenberg CR, Alling DW, Dumois JA, Notkins AL. 1993. Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Ann Intern Med 118:268272.[PubMed]
59. Le Cleach L, Trinquart L, Do G, Maruani A, Lebrun-Vignes B, Ravaud P, Chosidow O. 2014. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Cochrane Database Syst Rev 8:CD009036.[PubMed]
60. Tyring SK, Baker D, Snowden W. 2002. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years’ experience with acyclovir. J Infect Dis 186(Suppl 1):S40S46.[PubMed]
61. Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang ML, Schiffer JT, Koelle DM, Corey L, Wald A. 2012. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet 379:641647.[PubMed]
62. Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, Smiley ML. 1993. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 54:595605.[PubMed]
63. Huynh TH, Johnson MW, Comer GM, Fish DN. 2008. Vitreous penetration of orally administered valacyclovir. Am J Ophthalmol 145:682686.[PubMed]
64. Pouplin T, Pouplin JN, Van Toi P, Lindegardh N, Rogier van Doorn H, Hien TT, Farrar J, Török ME, Chau TT. 2011. Valacyclovir for herpes simplex encephalitis. Antimicrob Agents Chemother 55:36243626.[PubMed]
65. Jacobson MA, Gallant J, Wang LH, Coakley D, Weller S, Gary D, Squires L, Smiley ML, Blum MR, Feinberg J. 1994. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 38:15341540.[PubMed]
66. Bell WR, Chulay JD, Feinberg JE. 1997. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 76:369380.[PubMed]
67. Fife KH, Barbarash RA, Rudolph T, Degregorio B, Roth R The Valaciclovir International Herpes Simplex Virus Study Group. 1997. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. Sex Transm Dis 24:481486.[PubMed]
68. Tyring SK, Douglas JM Jr, Corey L, Spruance SL, Esmann J The Valaciclovir International Study Group. 1998. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol 134:185191.[PubMed]
69. Leone PA, Trottier S, Miller JM. 2002. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 34:958962.[PubMed]
70. Patel R, Bodsworth NJ, Woolley P, Peters B, Vejlsgaard G, Saari S, Gibb A, Robinson J International Valaciclovir HSV Study Group. 1997. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin Med 73:105109.[PubMed]
71. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. 1995. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 39:15461553.[PubMed]
72. McDonald EM, de Kock J, Ram FS. 2012. Antivirals for management of herpes zoster including ophthalmicus: a systematic review of high-quality randomized controlled trials. Antivir Ther 17:255264.[PubMed]
73. Lapolla W, Digiorgio C, Haitz K, Magel G, Mendoza N, Grady J, Lu W, Tyring S. 2011. Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. Arch Dermatol 147:901907.[PubMed]
74. Ljungman P, de La Camara R, Milpied N, Volin L, Russell CA, Crisp A, Webster A; Valacyclovir International Bone Marrow Transplant Study Group. 2002. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 99:30503056.[PubMed]
75. Griffiths PD, Feinberg JE, Fry J, Sabin C, Dix L, Gor D, Ansari A, Emery VC. 1998. The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 177:5764.[PubMed]
76. Shantha JG, Weissman HM, Debiec MR, Albini TA, Yeh S. 2015. Advances in the management of acute retinal necrosis. Int Ophthalmol Clin 55:113.[PubMed]
77. Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA. 1992. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 36:27472757.[PubMed]
78. Filer CW, Allen GD, Brown TA, Fowles SE, Hollis FJ, Mort EE, Prince WT, Ramji JV. 1994. Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects. Xenobiotica 24:357368.[PubMed]
79. Chong DY, Johnson MW, Huynh TH, Hall EF, Comer GM, Fish DN. 2009. Vitreous penetration of orally administered famciclovir. Am J Ophthalmol 148:3842.
80. Obach RS, Huynh P, Allen MC, Beedham C. 2004. Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44:719.[PubMed]
81. Mubareka S, Leung V, Aoki FY, Vinh DC. 2010. Famciclovir: a focus on efficacy and safety. Expert Opin Drug Saf 9:643658.[PubMed]
82. Sarisky RT, Bacon TH, Boon RJ, Duffy KE, Esser KM, Leary J, Locke LA, Nguyen TT, Quail MR, Saltzman R. 2003. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. Arch Virol 148:17571769.[PubMed]
83. Shin YK, Weinberg A, Spruance S, Bernard M, Bacon TH, Boon RJ, Levin MJ. 2003. Susceptibility of herpes simplex virus isolates to nucleoside analogues and the proportion of nucleoside-resistant variants after repeated topical application of penciclovir to recurrent herpes labialis. J Infect Dis 187:12411245.[PubMed]
84. Chosidow O, Drouault Y, Leconte-Veyriac F, Aymard M, Ortonne JP, Pouget F, Revuz J, Decazes JM, Malkin JE. 2001. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br J Dermatol 144:818824.[PubMed]
85. Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. 2006. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 42:813.[PubMed]
86. Spruance SL, Bodsworth N, Resnick H, Conant M, Oeuvray C, Gao J, Hamed K. 2006. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 55:4753.[PubMed]
87. Boon R, Goodman JJ, Martinez J, Marks GL, Gamble M, Welch C Penciclovir Cream Herpes Labialis Study Group. 2000. Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: a randomized, double-blind, placebo-controlled trial. Clin Ther 22:7690.[PubMed]
88. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, Jones T, Rea T, Boon R, Saltzman R Collaborative Famciclovir Herpes Zoster Study Group. 1995. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123:8996.[PubMed]
89. Boon RJ, Griffin DR. 1995. Efficacy of famciclovir in the treatment of herpes zoster: reduction of pain associated with zoster. Neurology 45(Suppl 8):S76S77.[PubMed]
90. Tyring S, Engst R, Corriveau C, Robillard N, Trottier S, Van Slycken S, Crann RA, Locke LA, Saltzman R, Palestine AG; Collaborative Famciclovir Ophthalmic Zoster Research Group. 2001. Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. Br J Ophthalmol 85:576581.[PubMed]
91. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. 2000. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 9:863869.[PubMed]
92. De Clercq E. 1984. The antiviral spectrum of (E)-5-(2-bromovinyl)-2’-deoxyuridine. J Antimicrob Chemother 14 (Suppl A):8595.
93. Shigeta S, Yokota T, Iwabuchi T, Baba M, Konno K, Ogata M, De Clercq E. 1983. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J Infect Dis 147:576584.[PubMed]
94. Fyfe JA. 1982. Differential phosphorylation of (E)-5-(2-bromovinyl)-2′-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus. Mol Pharmacol 21:432437.[PubMed]
95. De Clercq E. 2004. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem Pharmacol 68:23012315.[PubMed]
96. De Clercq E. 1986. Towards a selective chemotherapy of virus infections. Development of bromovinyldeoxyuridine as a highly potent and selective antiherpetic drug. Verh K Acad Geneeskd Belg 48:261290.[PubMed]
97. Wassilew SW, Wutzler P; Brivddin Herpes Zoster Study Group. 2003. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res 59:4956.[PubMed]
98. Keam SJ, Chapman TM, Figgitt DP. 2004. Brivudin (bromovinyl deoxyuridine). Drugs 64:20912097, discussion 2098–2099.[PubMed]
99. Andrei G, Balzarini J, Fiten P, De Clercq E, Opdenakker G, Snoeck R. 2005. Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin. J Virol 79:58635869.[PubMed]
100. Andrei G, De Clercq E, Snoeck R. 2004. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir? Antiviral Res 61:181187.[PubMed]
101. Wassilew S Collaborative Brivudin PHN Study Group. 2005. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol 19:4755.[PubMed]
102. Tricot G, De Clercq E, Boogaerts MA, Verwilghen RL. 1986. Oral bromovinyldeoxyuridine therapy for herpes simplex and varicella-zoster virus infections in severely immunosuppressed patients: a preliminary clinical trial. J Med Virol 18:1120.[PubMed]
103. Wutzler P, De Clercq E, Wutke K, Färber I. 1995. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. J Med Virol 46:252257.[PubMed]
104. Maudgal PC, De Clercq E. 1991. Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents. Curr Eye Res 10(Suppl):193199.[PubMed]
105. Birch CJ, Tyssen DP, Tachedjian G, Doherty R, Hayes K, Mijch A, Lucas CR. 1992. Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. J Infect Dis 166:108112.[PubMed]
106. Fardeau C, Langlois M, Mathys B, Rafales P, Nugier F, Godard V, Aymard M, Denis J. 1991. Emergence of cross-resistant herpes simplex virus following topical drug therapy in rabbit keratitis. Curr Eye Res 10(Suppl):151158.[PubMed]
107. Wilhelmus KR. 2015. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev 1:CD002898.[PubMed]
108. Field AK, Davies ME, DeWitt C, Perry HC, Liou R, Germershausen J, Karkas JD, Ashton WT, Johnston DB, Tolman RL. 1983. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA 80:41394143.[PubMed]
109. Prichard MN, Whitley RJ. 2014. The development of new therapies for human herpesvirus 6. Curr Opin Virol 9:148153.[PubMed]
110. Yuen GJ, Drusano GL, Fletcher C, Capparelli E, Connor JD, Lalezari JP, Drew L, Follansbee S, Busch D, Jacobson M. 1995. Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling. Antimicrob Agents Chemother 39:23502352.[PubMed]
111. Kuppermann BD, Quiceno JI, Flores-Aguilar M, Connor JD, Capparelli EV, Sherwood CH, Freeman WR. 1993. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis 168:15061509.[PubMed]
112. Markham A, Faulds D. 1994. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 48:455484.[PubMed]
113. Hardy D, Spector S, Polsky B, Crumpacker C, Horst C, Holland G, Freeman W, Heinemann MH, Sharuk G, Klystra J, Chown M. 1994. Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 Team. Eur J Clin Microbiol Infect Dis 13(Suppl 2):S34S40.[PubMed]
114. Jacobson MA, Kramer F, Bassiakos Y, Hooton T, Polsky B, Geheb H, O'Donnell JJ, Walker JD, Korvick JA, van der Horst C. 1994. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151. J Infect Dis 170:189193.[PubMed]
115. Manichanh C, Olivier-Aubron C, Lagarde JP, Aubin JT, Bossi P, Gautheret-Dejean A, Huraux JM, Agut H. 2001. Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo. J Gen Virol 82:27672776.[PubMed]
116. Isegawa Y, Hara J, Amo K, Osugi Y, Takemoto M, Yamanishi K, Fukunaga R, Shibata M, Ohshima A, Horiguchi Y, Sugimoto N. 2009. Human herpesvirus 6 ganciclovir-resistant strain with amino acid substitutions associated with the death of an allogeneic stem cell transplant recipient. J Clin Virol 44:1519.[PubMed]
117. Baldwin K. 2011. Ganciclovir-resistant human herpesvirus-6 encephalitis in a liver transplant patient: a case report. J Neurovirol 17:193195.[PubMed]
118. Chou S. 2015. Approach to drug-resistant cytomegalovirus in transplant recipients. Curr Opin Infect Dis 28:293299.[PubMed]
119. Lurain NS, Chou S. 2010. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 23:689712.[PubMed]
120. Kleiboeker S, Nutt J, Schindel B, Dannehl J, Hester J. 2014. Cytomegalovirus antiviral resistance: characterization of results from clinical specimens. Transpl Infect Dis 16:561567.[PubMed]
121. Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 176:6977.[PubMed]
122. Chen H, Beardsley GP, Coen DM. 2014. Mechanism of ganciclovir-induced chain termination revealed by resistant viral polymerase mutants with reduced exonuclease activity. Proc Natl Acad Sci USA 111:1746217467.[PubMed]
123. Drew WL, Miner RC, Busch DF, Follansbee SE, Gullett J, Mehalko SG, Gordon SM, Owen WF, Matthews TR, Buhles WC, DeArmond B. 1991. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 163:716719.[PubMed]
124. Minces LR, Nguyen MH, Mitsani D, Shields RK, Kwak EJ, Silveira FP, Abdel-Massih R, Pilewski JM, Crespo MM, Bermudez C, Bhama JK, Toyoda Y, Clancy CJ. 2014. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob Agents Chemother 58:128135.[PubMed]
125. Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP. 2007. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 45:439447.[PubMed]
126. Le Page AK, Jager MM, Iwasenko JM, Scott GM, Alain S, Rawlinson WD. 2013. Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis 56:10181029.[PubMed]
127. Hakki M, Chou S. 2011. The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis 24:605611.[PubMed]
128. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A Transplantation Society International CMV Consensus Group. 2013. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96:333360.[PubMed]
129. Shmueli E, Or R, Shapira MY, Resnick IB, Caplan O, Bdolah-Abram T, Wolf DG. 2014. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis 209:557561.[PubMed]
130. Choi SH, Hwang JY, Park KS, Kim Y, Lee SH, Yoo KH, Kang ES, Ahn JH, Sung KW, Koo HH, Kim YJ. 2014. The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations. Transpl Infect Dis 16:919929.[PubMed]
131. Choi KY, Sharon B, Balfour HH Jr, Belani K, Pozos TC, Schleiss MR. 2013. Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection. J Clin Virol 57:356360.[PubMed]
132. Gagermeier JP, Rusinak JD, Lurain NS, Alex CG, Dilling DF, Wigfield CH, Love RB. 2014. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients. Transpl Infect Dis 16:941950.[PubMed]
133. Drew WL. 1992. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 14:608615.[PubMed]
134. Studies of Ocular Complications of AIDS Research Group; in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. 1992. N Engl J Med 326:213220.
135. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA Roche Ganciclovir Study Group. 1999. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med 340:10631070.[PubMed]
136. Reed EC, Wolford JL, Kopecky KJ, Lilleby KE, Dandliker PS, Todaro JL, McDonald GB, Meyers JD. 1990. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann Intern Med 112:505510.[PubMed]
137. Erard V, Guthrie KA, Seo S, Smith J, Huang M, Chien J, Flowers ME, Corey L, Boeckh M. 2015. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis 61:3139.[PubMed]
138. Casper C, Nichols WG, Huang ML, Corey L, Wald A. 2004. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 103:16321634.[PubMed]
139. Brown F, Banken L, Saywell K, Arum I. 1999. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet 37:167176.[PubMed]
140. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, O'Grady J, Robinson C, To Z, Wren K, Banken L, Buhles W, Brown F. 2000. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 44:28112815.[PubMed]
141. Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, Atta MG, Wools-Kaloustian KK, Pham PA, Bruggeman LA, Lennox JL, Ray PE, Kalayjian RC HIV Medicine Association of the Infectious Diseases Society of America. 2014. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 59:e96e138.[PubMed]
142. Wang U, Yang A, Dong M, Busque S. 2013. Safety and effectiveness of valganciclovir for cytomegalovirus prophylaxis in solid organ transplant patients on hemodialysis [abstract]. Am J Transplant 13 (Suppl 5). http://www.atcmeetingabstracts.com/abstract/safety-and-effectiveness-of-valganciclovir-for-cytomegalovirus-prophylaxis-in-solid-organ-transplant-patients-on-hemodialysis/. Accessed March 30, 2016.
143. Perrottet N, Robatel C, Meylan P, Pascual M, Venetz JP, Aubert JD, Berger MM, Decosterd LA, Buclin T. 2008. Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. J Antimicrob Chemother 61:13321335.[PubMed]
144. Boivin G, Goyette N, Gilbert C, Covington E. 2005. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol 77:425429.[PubMed]
145. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. 2008. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 22:162170.[PubMed]
146. Curran M, Noble S. 2001. Valganciclovir. Drugs 61:11451150; discussion 1151–1142.
147. Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, Sgarabotto D, Tuncer M, Noronha IL, Hartmann A; Group VS, VICTOR Study Group. 2007. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 7:21062113.[PubMed]
148. Chmiel C, Speich R, Hofer M, Michel D, Mertens T, Weder W, Boehler A. 2008. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 46:831839.[PubMed]
149. Limaye AP. 2002. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 35:866872.[PubMed]
150. Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers ME, Stevens-Ayers T, Jerome KR, Leisenring W. 2015. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med 162:110.[PubMed]
151. Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA Team AS: A5030 Study Team. 2009. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. HIV Clin Trials 10:143152.[PubMed]
152. Mizushima D, Nishijima T, Gatanaga H, Tsukada K, Teruya K, Kikuchi Y, Oka S. 2013. Preemptive therapy prevents cytomegalovirus end-organ disease in treatment-naïve patients with advanced HIV-1 infection in the HAART era. PLoS One 8:e65348.[PubMed]
153. Mattioni S, Pavie J, Porcher R, Scieux C, Denis B, De Castro N, Simon F, Molina JM. 2015. Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia. Int J STD AIDS 26:306312.[PubMed]